Support in transitioning your eligible NVAF and VTE patients from warfarin to a DOAC in response to COVID-19
Given the NHS England1 clinical guide for the management of anticoagulant services during the Coronavirus pandemic, and recent guidelines published by Royal Pharmaceutical Society to consider transitioning patients from warfarin to a DOAC where appropriate1, Bayer is determined to support and assist healthcare professionals and patients, wherever possible, during this unprecedented, public health crisis. Click below to find out more:
Download the following resources:
Other useful information for Healthcare Professionals
For further information on Guidance for the safe transitioning of warfarin to
direct oral anticoagulants (DOACs) for patients with non-valvular AF and venous thromboembolism (DVT / PE) during the coronavirus pandemic:
> Royal Pharmaceutical Society
1. Royal Pharmaceutical Society www.rpharms.com Accessed 30 March 2020
We are regularly updating our website with new resources to support you and your patients. Please click here to subscribe to receive electronic communications about Bayer’s products, services and events.
To access the latest version of the Xarelto 2.5mg, 10mg and 15/20 mg Summary of Product Characteristics (SmPC) as well as Xarelto Patient Information Leaflet (PIL), please click on the following link eMC Widget
Reporting adverse events and quality complaints
This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.
If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 0118 206 3500 or Email: firstname.lastname@example.org
Further information is available on the "contact" tab at www.bayer.co.uk.